NASDAQ:CYTX - Cytori Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.01 (-0.52%)
Get New Cytori Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cytori Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.93.

This chart shows the closing price for CYTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Cytori Therapeutics. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/1/2019Maxim GroupReiterated RatingHoldLow
12/3/2018Maxim GroupReiterated RatingHoldMedium
11/15/2018Maxim GroupReiterated RatingHoldHigh
9/18/2018HC WainwrightReiterated RatingBuy$5.00High
8/15/2018Maxim GroupDowngradeBuy ➝ HoldHigh
8/15/2018HC WainwrightLower Price TargetBuy$6.00 ➝ $5.00High
7/11/2018HC WainwrightReiterated RatingBuy$6.00High
5/14/2018HC WainwrightSet Price TargetBuy$40.00Medium
5/11/2018Maxim GroupSet Price TargetBuy$20.00Low
5/7/2018HC WainwrightInitiated CoverageBuy$40.00Low
4/30/2018Maxim GroupSet Price TargetBuy$20.00Low
3/28/2018Maxim GroupSet Price TargetBuy$20.00High
3/9/2018B. RileyUpgradeNeutral ➝ BuyLow
3/9/2018Maxim GroupSet Price TargetBuy$40.00 ➝ $20.00Medium
2/22/2018LaidlawReiterated RatingBuy ➝ Buy$16.50Medium
2/13/2018Maxim GroupSet Price TargetBuy$40.00Low
1/22/2018Maxim GroupSet Price TargetBuy$50.00Low
1/5/2018Maxim GroupSet Price TargetBuy$50.00High
11/13/2017Maxim GroupSet Price TargetBuy$50.00N/A
11/7/2017B. RileyReiterated RatingHoldN/A
10/19/2017Maxim GroupSet Price TargetBuy$50.00N/A
8/16/2017B. RileyReiterated RatingNeutralMedium
8/11/2017B. RileyReiterated RatingNeutralMedium
8/11/2017Maxim GroupSet Price TargetBuy ➝ Buy$100.00 ➝ $50.00High
7/30/2017B. RileyReiterated RatingNeutralMedium
7/25/2017B. RileyDowngradeBuy ➝ NeutralLow
7/10/2017Maxim GroupSet Price TargetBuy$100.00High
5/31/2017Maxim GroupSet Price TargetBuy$100.00Medium
5/15/2017B. RileyReiterated RatingBuy$23.00High
5/13/2017Maxim GroupSet Price TargetBuy$100.00Medium
5/10/2017B. RileyReiterated RatingBuy$23.00Low
3/27/2017B. RileyReiterated RatingBuy$67.50Medium
3/25/2017Maxim GroupSet Price TargetBuy$100.00Low
3/22/2017B. RileyReiterated RatingBuy$67.50Low
2/21/2017B. RileyReiterated RatingBuy$67.50N/A
2/16/2017B. RileyReiterated RatingBuy$67.50N/A
2/15/2017Maxim GroupBoost Price TargetBuy$60.00 ➝ $100.00N/A
1/24/2017Maxim GroupReiterated RatingBuy$60.00N/A
12/21/2016B. RileyInitiated CoverageBuy$57.50N/A
12/16/2016B. RileyInitiated CoverageBuy$57.50N/A
12/6/2016Maxim GroupReiterated RatingBuy$50.00N/A
10/24/2016Maxim GroupSet Price TargetBuy$50.00N/A
9/14/2016Maxim GroupReiterated RatingBuy$50.00N/A
8/31/2016Maxim GroupSet Price TargetBuy$50.00N/A
8/5/2016Maxim GroupSet Price TargetBuy$50.00N/A
(Data available from 8/5/2016 forward)
Cytori Therapeutics logo
Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $1.93
Low: $1.82
High: $1.94

50 Day Range

MA: $0.20
Low: $0.20
High: $0.21

52 Week Range

Now: $1.93
Low: $0.20
High: $0.75


235,254 shs

Average Volume

915,302 shs

Market Capitalization

$42.77 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Cytori Therapeutics?

The following Wall Street analysts have issued reports on Cytori Therapeutics in the last year:
View the latest analyst ratings for CYTX.

What is the current price target for Cytori Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cytori Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cytori Therapeutics in the next year.
View the latest price targets for CYTX.

What is the current consensus analyst rating for Cytori Therapeutics?

Cytori Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CYTX.

What other companies compete with Cytori Therapeutics?

How do I contact Cytori Therapeutics' investor relations team?

Cytori Therapeutics' physical mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is 858-458-0900 and its investor relations email address is [email protected] The official website for Cytori Therapeutics is